TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DISULFIRAM

DISULFIRAM Acetyl Aldehyde Dehydrogenase Inhibitors
Approved 1981-03-31
8
Indications
--
Phase 3 Trials
44
Years on Market

Details

Status
Prescription
First Approved
1981-03-31
Routes
ORAL
Dosage Forms
TABLET

DISULFIRAM Approval History

Loading approval history...

What DISULFIRAM Treats

1 indications

DISULFIRAM is approved for 1 conditions since its original approval in 1981. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Alcoholism
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DISULFIRAM FDA Label Details

Pro

Indications & Usage

Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.